FDA Clears IND for Oral Elraglusib, Paving Way for New Cancer Drug Study
ACTU has more than doubled off its 52-week low of $1.58.
Summary
Actuate Therapeutics announced FDA Investigational New Drug (IND) clearance for its oral formulation of elraglusib, enabling the company to initiate a Phase 1/2 study. This strategic move prioritizes an oral tablet designed for enhanced patient convenience, broader clinical utility, and improved drug exposure, building on positive Phase 2 data from the IV formulation in metastatic pancreatic cancer. This development is a critical positive catalyst for Actuate, especially given its recent 10-K filing which included a going concern warning with cash expected to last only until July 2026. Advancing its lead asset with a potentially superior formulation is vital for the company's long-term viability and ability to attract future funding or partnerships. Investors should monitor the initiation and progress of the Phase 1/2 study, expected in the second half of 2026, and any subsequent financing activities.
At the time of this announcement, ACTU was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.2M. The 52-week trading range was $1.58 to $11.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.